base metals investing Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery ) Development Candidates for the Treatment of Alzheimer's Disease
base metals investing Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
base metals investing Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base metals investing Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease Conference
